with type 1 diabetes must carefully balance insulin doses with eating and daily
activities throughout the day and night – and still run the risk of dangerous
high or low blood sugar levels. To help
manage this daily challenge, a continuous glucose monitor (CGM) device provides
continuous "real-time" readings and data about trends in glucose
levels. The device can allow people to understand the level of their glucose
and whether it is rising or falling, and to intervene by eating food or taking
insulin to prevent it from going too high or too low.
practice guidelines released by the Endocrine
Society recommend settings where people are most likely to benefit from the
use of continuous glucose monitoring (CGM). The guidelines were published online
in the October issue of the Journal of Clinical Endocrinology and Metabolism.
from the guidelines include:
Children and adolescents with T1D use currently approved CGM devices to assist
in maintaining target HbA1c levels of
less than 7.0%, while
limiting the risk of hypoglycemia.
Use of CGM devices by adults with T1D who have demonstrated they can use these
devices on a nearly daily basis.
• CGM devices should not be used alone for glucose management in the intensive
care unit or operating room, until further studies provide evidence for
accuracy and safety.
to David Klonoff, MD, chair of the task force that authored the guidelines, "CGM
can be a beneficial tool to help maintain target levels of glycemia and limit
the risk of hypoglycemia."
These recommendations build on the steps JDRF has taken to accelerate the development, regulatory
approval, and clinical acceptance of continuous glucose monitoring to ensure
that people with type 1 diabetes have access to technologies that will improve
blood glucose control.
Furthermore, JDRF is leading the development of a closed-loop
pancreas system, to improve the lives of people with T1D by enabling them
to maintain better control of their blood sugar. Although not a cure, we expect artificial pancreas systems
to be external devices comprised of insulin pumps, continuous glucose sensors,
and an algorithm to communicate between the two. To help speed its development, JDRF recently
launched the Artificial
Pancreas Campaign Petition to convince the FDA to adopt clinical expert
recommendations. Additional information
about the campaign and the petition is available by visiting the JDRF Advocacy website.